Spotlight Session - Databases

(C01) Agreement of COVID-19 Incidence Between the Authoritative Data and Real-World Evidence in England

(C02) Anonymized tokenization technology to link real world data and assess the potential for exposure misclassification for pharmacoepidemiology research

(C03) Contemporary pharmacoepidemiology practice for real world data source identification and feasibility assessment – Results from an ISPE-sponsored online survey

(C04) European Rare Disease Registries: A Collaborative Effort to Assess the Quality and Suitability of Registries to Describe the Natural History of Disease and Treatment Landscape of Spinal Muscular Atrophy

(C05) Phased Target Trial Design and Meta-Analysis in a Head-to-Head Treatment Comparison

(C06) The risk of incident dementia and Alzheimer’s disease after the use of centrally-acting versus non-centrally acting angiotensin-converting enzyme inhibitors: a target trial emulation study

(C08) Using Historical RCT Controls to Contextualize Necessity of Unblinding of Serious Adverse Events and Adverse Events of Special Interest – Conceptual Framework and Database Development